Status:
COMPLETED
Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients
Lead Sponsor:
University Hospital, Toulouse
Collaborating Sponsors:
French Innovative Leukemia Organisation
Conditions:
Acute Myeloid Leukemia
Eligibility:
All Genders
60+ years
Phase:
PHASE2
Brief Summary
These study is designed to evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin in elderly AML.
Detailed Description
Evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin
Eligibility Criteria
Inclusion
- Informed consent
- de novo or secondary LAM (CML excluded) not elligible for intensive chemotherapy.
- Previously untreated
Exclusion
- Renal impairment (serum creatinin \>2N)
- Hepatic impairment (TGO ou TGP \> 5N), une cholestase (Phosphatases Alcalines or gamma-GT \> 5N),bilirubin \> 3N
- Blast crisis CML
- Acute Promyelocytic Leukemia.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00235560
Start Date
June 1 2005
End Date
June 1 2008
Last Update
February 29 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'Hématologie, CHU
Angers, France, 49100
2
Service d'Hématologie, Hôpital Jean Minjoz
Besançon, France, 25000
3
Service d'Hématologie CHU Purpan
Toulouse, France, 31059